Background
Methods
Study design and patients
GPC3 expression in tumor
Flow cytometry
Soluble protein measurements
DNA polymorphisms
Statistical analysis
Results
Latent feature analysis
Sub-population | Drug Identifier | F1 | F2 | F3 | Average(*) num. of patients | Mean PFS (month) | Median PFS (month) |
---|---|---|---|---|---|---|---|
1. | 0 | 0 | 0 | 0 | 33.37 | 3.06 | 1.65 |
2. | 0 | 0 | 1 | 0 | 4.07 | 2.29 | 2.24 |
3. | 0 | 1 | 0 | 0 | 17.84 | 2.72 | 1.81 |
4. | 0 | 1 | 1 | 0 | 4.72 | 7.05 | 7.18 |
5. | 1 | 0 | 0 | 0 | 51.52 | 3.22 | 2.55 |
6. | 1 | 0 | 0 | 1 | 16.77 | 4.17 | 3.65 |
7. | 1 | 0 | 1 | 0 | 8.38 | 1.74 | 1.33 |
8. | 1 | 0 | 1 | 1 | 2.07 | 2.69 | 2.65 |
9. | 1 | 1 | 0 | 0 | 29.88 | 3.36 | 2.03 |
10. | 1 | 1 | 0 | 1 | 4.90 | 4.44 | 4.34 |
11. | 1 | 1 | 1 | 0 | 4.53 | 6.31 | 5.31 |
12. | 1 | 1 | 1 | 1 | 1.94 | 10.04 | 10.01 |
Total | 120.0 | 63.82 | 25.72 | 25.69 | 180 | 3.44 | 2.04 |
Continuous Variables | Effect Size | p-value |
---|---|---|
AFP | 3.65 | 1.31e-07 |
GPC3 membrane | 1.30 | 1.53e-21 |
GPC3 cytoplasmic | 0.69 | 2.08e-16 |
sGPC3 11/96 | 0.47 | 1.34e-04 |
sGPC3 30/57 | 0.40 | 1.53e-05 |
sGPC3 30/607 | 0.34 | 6.21e-10 |
sGPC3 114/165 | 0.32 | 2.48e-10 |
Continuous Variables | Effect Size | p-value |
---|---|---|
CD3/CD16 necrotic | 3.94 | 1.29e-17 |
%Necrotic | 3.91 | 9.39e-18 |
CD3/CD16 viable | −1.27 | 1.29e-17 |
%Viable | −1.24 | 9.39e-18 |
Continuous Variables | Effect Size | p-value |
---|---|---|
CD56dimCD16bright | 1.27 | 2.18e-09 |
NK | 1.24 | 2.13e-10 |
CD56-CD16+ | 0.61 | 2.19e-06 |
CD56dimCD16- | 0.42 | 1.04e-05 |
CD8 NK | 0.37 | 7.13e-08 |
DN | 0.27 | 3.73e-05 |
CD16 | 0.24 | 6.06e-10 |
NKP46 | 0.22 | 1.14e-09 |
CD8 | 0.20 | 3.44e-09 |
CD45 | 0.14 | 5.09e-11 |
CD3 | 0.13 | 1.49e-08 |
CD4 | 0.12 | 5.06e-06 |
Analysis of subpopulations
Continuous Variables | Effect Size | p-value |
---|---|---|
%Necrotic | 2.73 | 1.86e-04 |
CD3/CD16 necrotic | 2.63 | 2.85e-04 |
%Viable | −0.86 | 1.86e-04 |
CD3/CD16 viable | −0.85 | 2.85e-04 |
Continuous Variables | Effect Size | p-value |
---|---|---|
CD56dimCD16bright | 1.36 | 1.76e-09 |
NK | 1.33 | 9.51e-11 |
CD56-CD16+ | 0.66 | 1.26e-06 |
DP | 0.59 | 2.14e-04 |
CD56dimCD16- | 0.44 | 4.39e-06 |
CD8 NK | 0.39 | 9.50e-08 |
DN | 0.30 | 3.58e-05 |
CD16 | 0.25 | 3.36e-10 |
NKP46 | 0.25 | 3.29e-10 |
B | 0.21 | 2.29e-04 |
CD8 | 0.21 | 2.67e-09 |
CD45 | 0.15 | 3.75e-11 |
CD3 | 0.14 | 1.00e-08 |
CD4 | 0.14 | 1.48e-06 |
High drug exposure analysis
Sub-population | Drug Identifier | F1 | F2 | F3 | Average num. of patients | Mean PFS (months) | Median PFS (months) |
---|---|---|---|---|---|---|---|
1. | 0 | 0 | 0 | 0 | 33.16 | 3.07 | 1.65 |
2. | 0 | 0 | 1 | 0 | 4.17 | 2.30 | 2.21 |
3. | 0 | 1 | 0 | 0 | 17.96 | 2.70 | 1.81 |
4. | 0 | 1 | 1 | 0 | 4.71 | 7.02 | 7.15 |
5. | 1 | 0 | 0 | 0 | 25.67 | 4.15 | 3.93 |
6. | 1 | 0 | 0 | 1 | 6.72 | 4.64 | 4.23 |
7. | 1 | 0 | 1 | 0 | 4.23 | 2.96 | 2.29 |
8. | 1 | 0 | 1 | 1 | 1.37 | 3.69 | 3.67 |
9. | 1 | 1 | 0 | 0 | 14.63 | 3.62 | 2.66 |
10. | 1 | 1 | 0 | 1 | 1.55 | 5.94 | 5.93 |
11. | 1 | 1 | 1 | 0 | 3.86 | 6.23 | 5.37 |
12. | 1 | 1 | 1 | 1 | 1.98 | 10.63 | 10.62 |
Total | 60.00 | 44.69 | 20.31 | 11.61 | 120 | 3.78 | 2.76 |